28 de octubre de 2015 / 12:41 / en 2 años

BRIEF-GSK CEO still expects respiratory to return to growth in 2016

Oct 28 (Reuters) - GlaxoSmithKline Plc CEO Andrew Witty told reporters:

* still expects respiratory to return to growth in 2016

* expects emerging markets to improve in q4 and sees decent growth next year

* says pricing a big focus in u.s., shows need to have business strategy not totally dependent on price

* seeing disruption in some emerging markets, including brazil, russia, mideast

* q3 progress means very optimistic will get to consumer margins of at least 20 percent Further company coverage: (Reporting by UK bureau)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below